Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ventura BioMed Investors is a venture capital firm dedicated to the life sciences sector, founded by Dr. Andreas Jenne and Dr. Kurt Rudolf Schwarz. Established in Europe, the firm focuses on supporting early-stage life science companies that are developing innovative therapies and technologies. The founders bring extensive experience from the biotech and pharmaceutical industries, which informs their investment strategy.
Currently, Ventura BioMed Investors manages a portfolio of five companies and typically invests between EUR 1 million and EUR 5 million per company. The firm collaborates with other funds to maximize the impact of its investments. Their investment platform, Ventura Ace, includes selected private investors, enhancing the support available to portfolio companies.
Notable milestones include the establishment of a strong portfolio in the biotech sector, with a focus on pioneering technologies and therapies. The firm is strategically positioned to leverage its founders' expertise and connections within the European life sciences landscape.
Ventura BioMed Investors emphasizes investments in early-stage life science companies across Europe, particularly in the biotech and healthcare sectors. The firm typically invests between EUR 1 million and EUR 5 million per company, which allows for significant support during the critical early stages of development. Their investment strategy is centered on collaborating with other funds to enhance the overall impact of their investments.
The firm seeks companies that are developing pioneering technologies and innovative therapies, particularly those that address unmet medical needs. Ventura BioMed Investors looks for founders with strong backgrounds in their respective fields and a clear vision for their companies. The firm prefers to engage in co-investment opportunities, which allows them to pool resources and expertise with other investors.
Overall, Ventura BioMed Investors is committed to fostering the growth of early-stage life sciences companies that are poised to make significant contributions to healthcare and biotechnology.
Ventura BioMed Investors has a focused portfolio of five companies, each contributing to advancements in the life sciences sector:
Dr. Andreas Jenne - Co-Founder: Dr. Jenne has extensive experience in the biotech industry, having held various leadership roles in pharmaceutical companies. His expertise lies in drug development and commercialization strategies.
Dr. Kurt Rudolf Schwarz - Co-Founder: Dr. Schwarz brings a wealth of knowledge from his background in the pharmaceutical sector. He has a strong track record in managing biotech investments and developing innovative therapies.
To pitch to Ventura BioMed Investors, founders should visit their website at ventura-biomed.com. It is recommended to include a detailed business plan, an overview of the technology or therapy being developed, and information about the founding team. The firm prefers pitches that clearly outline the market opportunity and the competitive landscape.
Response times can vary, but founders should expect a thorough review process. Warm introductions are beneficial, as they can enhance the likelihood of receiving a timely response.
What are the investment criteria for Ventura BioMed Investors?
Ventura BioMed Investors focuses on early-stage life science companies in Europe, particularly in the biotech and healthcare sectors. They typically invest between EUR 1 million and EUR 5 million per company.
How can I apply or pitch to Ventura BioMed Investors?
Founders can submit their pitches through the Ventura BioMed Investors website at ventura-biomed.com. It is advisable to include a comprehensive business plan and details about the technology or therapy being developed.
What makes Ventura BioMed Investors different from other firms?
The firm leverages the extensive industry experience of its founders, Dr. Andreas Jenne and Dr. Kurt Rudolf Schwarz, to provide valuable insights and support to portfolio companies. Their collaborative investment approach enhances the impact of their investments.
What is the geographic scope of Ventura BioMed Investors?
Ventura BioMed Investors primarily focuses on early-stage life science companies located in Europe, aiming to support innovative therapies and technologies within this region.
What is the post-investment involvement like?
Ventura BioMed Investors actively engages with its portfolio companies, providing mentorship and access to a network of industry experts and private investors through their investment platform, Ventura Ace.
What is the typical check size for investments?
The firm typically invests between EUR 1 million and EUR 5 million per company, allowing for substantial support during the early stages of development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.